Tenaya Therapeutics (TNYA) Price & Analysis

Compare

3,065 Followers

TNYA Stock Chart & Stats

$1.33

-$0.05(-3.69%)

At close: Jan 08 4:00 PM EST

$1.33

-$0.05(-3.69%)

Day’s Range― - ―

52-Week Range$0.36 - $2.35

Previous CloseN/A

Volume1.07M

Average Volume (3M)4.00M

Market Cap

$182.32M

Enterprise Value$95.51M

Total Cash (Recent Filing)$56.31M

Total Debt (Recent Filing)$11.53M

Price to Earnings (P/E)―

Beta2.75

Next Earnings

Mar 24, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding216,505,890

10 Day Avg. Volume2,873,734

30 Day Avg. Volume4,003,933

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.31

Price to Sales (P/S)0.00

P/FCF Ratio-1.33

Enterprise Value/Market Cap0.52

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-24.19

Enterprise Value/Ebitda-1.10

Forecast

1Y Price Target

$9.14

Price Target Upside587.43% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Milestones And Regulatory AlignmentUpcoming clinical readouts across lead programs and potential alignment with regulators on pivotal study design could provide clearer approval pathways and act as major positive catalysts for the stock.

Early Clinical Efficacy And SafetyBiopsy and follow-up signals showing increased PKP2 protein expression alongside reductions in arrhythmia burden and a tolerable safety profile support clinical proof-of-concept and may boost investor confidence.

Financial RunwayA strengthened cash position supports continued clinical development and regulatory interactions, reducing near-term financing uncertainty and enabling execution of planned milestones.

Bears Say

Competitive Efficacy ComparisonReported protein changes appear smaller than those disclosed for competing gene therapies, which may pressure the program's perceived competitiveness and market potential.

Limited And Mixed Clinical DataSmall patient cohorts and heterogeneous outcomes, including instances with no measurable expression, make it hard to draw definitive efficacy conclusions and increase program risk.

Regulatory Holds And Monitoring RequirementsFDA-imposed clinical holds requiring standardized patient monitoring and immunosuppression protocols create execution risk and can delay enrollment and regulatory progress.

Tenaya Therapeutics News

Tenaya Therapeutics announces 2026 strategic priorities

Tenaya Therapeutics (TNYA) provided an update on its clinical development programs and outlined its strategic priorities for 2026....

27d ago

TNYA

Tenaya Therapeutics price target lowered to $2 from $5 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $2 from $5 and keeps an...

28d ago

TNYA

Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan

Tenaya Therapeutics ( ($TNYA) ) has issued an update. On January 28, 2026, Tenaya Therapeutics disclosed that it...

6d ago

TNYA

Tenaya Therapeutics: 2026 Clinical Milestones, FDA Pivotal Pathway, and Strengthened Balance Sheet Support Buy Rating

William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating today....

27d ago

TNYA

Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target...

27d ago

TNYA

Tenaya Therapeutics announces orderly board leadership transition

Tenaya Therapeutics ( ($TNYA) ) just unveiled an announcement. Tenaya Therapeutics announced that board member David Goeddel submitted...

1M ago

TNYA

Tenaya Therapeutics price target lowered to $4 from $6 at Canaccord

Canaccord lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $4 from $6 and keeps a Buy...

2M ago

TNYA

Promising Initial Data and Safety Profile Justify Buy Rating for Tenaya Therapeutics’ TN-401

Cory Jubinville, PhD, an analyst from LifeSci Capital, reiterated the Buy rating on Tenaya Therapeutics. The associated price...

2M ago

TNYA

Tenaya Therapeutics Announces Public Offering Pricing

Tenaya Therapeutics ( ($TNYA) ) has provided an update. On December 11, 2025, Tenaya Therapeutics announced the pricing...

2M ago

TNYA

Promising Clinical Developments and FDA Approval Boost Tenaya Therapeutics’ Buy Rating

Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Tenaya Therapeutics and decreased the price target...

2M ago

TNYA

Tenaya Therapeutics price target lowered to $3 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $3 from $5 and keeps a...

2M ago

TNYA

3 ‘Strong Buy’ Stocks to Buy Today, 12/12/2025, According to Top Analysts

Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all...

2M ago

AARD

EVLV

Tenaya Therapeutics price target lowered to $8 from $9 at Chardan

Chardan analyst Geulah Livshits lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $8 from $9 and...

2M ago

LXEO

RCKT

Tenaya Therapeutics 50M share Spot Secondary priced at $1.20

Leerink and Piper Sandler acted as joint book running managers for the offering. Published first on TheFly –...

2M ago

TNYA

TNYA FAQ

What was Tenaya Therapeutics’s price range in the past 12 months?

Tenaya Therapeutics lowest stock price was $0.36 and its highest was $2.35 in the past 12 months.

What is Tenaya Therapeutics’s market cap?

Tenaya Therapeutics’s market cap is $182.32M.

When is Tenaya Therapeutics’s upcoming earnings report date?

Tenaya Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 47 days.

How were Tenaya Therapeutics’s earnings last quarter?

Tenaya Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.148 by $0.028.

Is Tenaya Therapeutics overvalued?

According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tenaya Therapeutics pay dividends?

Tenaya Therapeutics does not currently pay dividends.

What is Tenaya Therapeutics’s EPS estimate?

Tenaya Therapeutics’s EPS estimate is -0.12.

How many shares outstanding does Tenaya Therapeutics have?

Tenaya Therapeutics has 216,505,890 shares outstanding.

What happened to Tenaya Therapeutics’s price movement after its last earnings report?

Tenaya Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.148. Following the earnings report the stock price went up 11.719%.

Which hedge fund is a major shareholder of Tenaya Therapeutics?

Currently, no hedge funds are holding shares in TNYA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tenaya Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-96.44%

Trailing 12-Months

Asset Growth

-25.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Tenaya Therapeutics (TNYA) Earnings & Revenues

Historic Earnings Reports

TNYA Stock 12 Month Forecast

Average Price Target

$9.14

▲(587.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","41":"$41","-1":"-$1","9.5":"$9.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.142857142857142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,9.5,20,30.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.901,3.908615384615384,6.9162307692307685,9.923846153846153,12.931461538461537,15.939076923076922,18.946692307692306,21.95430769230769,24.961923076923075,27.96953846153846,30.977153846153843,33.98476923076923,36.992384615384616,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.901,1.534989010989011,2.168978021978022,2.802967032967033,3.4369560439560436,4.070945054945055,4.704934065934066,5.338923076923076,5.972912087912087,6.606901098901099,7.24089010989011,7.87487912087912,8.508868131868132,{"y":9.142857142857142,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.901,0.9855384615384616,1.0700769230769231,1.1546153846153846,1.239153846153846,1.3236923076923077,1.4082307692307692,1.4927692307692308,1.5773076923076923,1.6618461538461538,1.7463846153846154,1.8309230769230769,1.9154615384615383,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.544,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.603,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.711,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.901,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >